Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 50 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $482.98, for a total value of $24,149.00. Following the completion of the transaction, the director directly owned 470 shares in the company, valued at approximately $227,000.60. This trade represents a 9.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Up 1.1%

Shares of United Therapeutics stock traded up $5.48 during trading on Friday, reaching $493.99. 638,832 shares of the company were exchanged, compared to its average volume of 578,838. The business has a 50-day moving average price of $456.99 and a 200-day moving average price of $372.72. The firm has a market capitalization of $21.27 billion, a price-to-earnings ratio of 18.72, a P/E/G ratio of 4.81 and a beta of 0.86. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $496.73.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company earned $6.39 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB grew its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $29,000. Abich Financial Wealth Management LLC bought a new position in shares of United Therapeutics in the third quarter valued at $44,000. SVB Wealth LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. Finally, WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company raised their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.